Want to see SSII full AI Analyst Report?
Top Page
SS Innovations International
(NASDAQ:SSII)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.50
▼(-45.48% Downside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by ongoing losses and heavy cash burn, alongside a weak technical setup (below key moving averages with negative MACD). Improving revenue growth and gross margin and a currently low-leverage balance sheet provide support, but dilution/execution risks from the ATM program and leadership change keep the overall outlook constrained.
Positive Factors
Revenue growth & margin expansion
Sustained top-line growth and a rising gross margin reflect improving unit economics from system sales and consumables. Better margins reduce the cash needed per incremental sale, supporting a durable path to scale and eventual profitability if revenue momentum continues.
Negative Factors
Negative operating & free cash flow
Persistent negative operating and free cash flow indicate the business consumes cash to scale systems, instruments and service infrastructure. Continued cash burn forces dependence on external financing, constrains reinvestment, and raises execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & margin expansion
Sustained top-line growth and a rising gross margin reflect improving unit economics from system sales and consumables. Better margins reduce the cash needed per incremental sale, supporting a durable path to scale and eventual profitability if revenue momentum continues.
Read all positive factors
SS Innovations International (SSII) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$694.46M
Dividend YieldN/A
Average Volume (3M)59.94K
Price to Earnings (P/E)―
Beta (1Y)9.22
Revenue Growth119.23%
EPS Growth40.14%
CountryUS
Employees378
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.05
Shares Outstanding200,131,530
10 Day Avg. Volume56,593
30 Day Avg. Volume59,936
Financial Highlights & Ratios
PEG Ratio2.12
Price to Book (P/B)28.24
Price to Sales (P/S)25.40
P/FCF Ratio-48.61
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue13.32
Enterprise Value/Gross Profit27.52
Enterprise Value/Ebitda-174.01
Forecast
1Y Price Target
$7.00Price Target Upside9.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SS Innovations International Business Overview & Revenue Model
Company Description
SS Innovations International, Inc., situated in Fort Lauderdale, Florida, focuses on the development of sophisticated robotic systems for surgical use. Their offerings encompass the SSI Mantra, a specialized surgical robot, and SSI Mudra, a suite ...
How the Company Makes Money
Revenue is primarily generated through the sale and/or placement of robotic surgical systems to hospitals and surgical centers, and from recurring procedure-driven demand for consumables and accessories used with those systems (e.g., single-use or...
SS Innovations International Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
67
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.45M | 42.48M | 20.65M | 5.88M | 1.46M | 0.00 |
| Gross Profit | 23.44M | 19.54M | 8.45M | 713.45K | 489.59K | -18.79K |
| EBITDA | -3.71M | -5.98M | -17.74M | -20.26M | -5.31M | -1.47M |
| Net Income | -10.03M | -12.13M | -19.15M | -20.94M | -5.60M | -1.48M |
Balance Sheet | ||||||
| Total Assets | 90.55M | 74.23M | 42.39M | 25.48M | 6.98M | 428.61K |
| Cash, Cash Equivalents and Short-Term Investments | 15.98M | 3.21M | 466.50K | 7.03M | 217.18K | 405.77K |
| Total Debt | 13.82M | 14.36M | 18.20M | 8.22M | 8.27M | 145.00K |
| Total Liabilities | 36.02M | 36.01M | 28.93M | 11.18M | 9.66M | 287.28K |
| Stockholders Equity | 54.52M | 38.22M | 13.46M | 14.30M | -2.68M | 141.33K |
Cash Flow | ||||||
| Free Cash Flow | -17.59M | -22.20M | -10.16M | -15.81M | -1.44M | -363.03K |
| Operating Cash Flow | -14.75M | -18.54M | -9.50M | -15.36M | -5.99M | -363.03K |
| Investing Cash Flow | -2.84M | -3.66M | -661.48K | -453.33K | 240.82K | 38.15K |
| Financing Cash Flow | 21.92M | 26.17M | 9.43M | 22.80M | 5.90M | 569.95K |
SS Innovations International Technical Analysis
Negative
6.42
Price Trends
3.94
Negative
4.26
Negative
5.33
Negative
Market Momentum
-0.15
Negative
40.16
Neutral
48.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SSII, the sentiment is Negative. The current price of 6.42 is above the 20-day moving average (MA) of 3.62, above the 50-day MA of 3.94, and above the 200-day MA of 5.33, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 40.16 is Neutral, neither overbought nor oversold. The STOCH value of 48.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SSII.
SS Innovations International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.08B | 20.28 | 5.40% | 2.02% | 4.78% | -53.80% | |
57 Neutral | $1.46B | -2.89 | -47.65% | ― | 1.24% | -1605.54% | |
57 Neutral | $2.60B | -59.78 | -225.86% | ― | 34.86% | 52.13% | |
54 Neutral | $1.15B | 94.18 | 2.66% | ― | 17.59% | ― | |
53 Neutral | $1.11B | -11.61 | -68.29% | ― | 4.54% | 49.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $694.46M | ― | -23.00% | ― | 119.23% | 40.14% |
* Healthcare Sector Average
SSII
SS Innovations International
3.34
-2.55
-43.29%
CNMD
Conmed
35.95
-15.93
-30.71%
AORT
Artivion
23.61
-7.49
-24.08%
IART
Integra Lifesciences
18.76
6.49
52.89%
TNDM
Tandem Diabetes Care
16.24
-2.40
-12.88%
ESTA
Establishment Labs Holdings
88.38
45.67
106.93%
SS Innovations International Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
SS Innovations Launches $50 Million At-The-Market Program
Positive
Jun 18, 2026
On June 18, 2026, SS Innovations International entered into an ATM Sales Agreement with Virtu Americas LLC to sell up to $50 million of its common stock through an at-the-market offering program, with Virtu acting as exclusive sales agent or princ...
Business Operations and StrategyFinancial Disclosures
SS Innovations Showcases Growth Strategy in Investor Presentation
Positive
Jun 15, 2026
In June 2026, SS Innovations International released an investor presentation outlining its position as a fast-growing surgical robotics company focused on advanced but affordable robotic systems to expand access to minimally invasive surgery globa...
Business Operations and StrategyProduct-Related Announcements
SS Innovations Showcases Record-Breaking Cardiac Robotic Telesurgery
Positive
Jun 4, 2026
On May 26, 2026, SS Innovations International’s SSi Mantra system enabled what the company says is the world’s longest‑distance robotic telesurgery, a robot‑assisted cardiac procedure performed from Georgetown, Guyana on a ...
Business Operations and StrategyExecutive/Board Changes
SS Innovations Announces Departure of COO and CFO
Negative
May 26, 2026
On May 18, 2026, SS Innovations International announced that Milan Rao had informed the company he would step down from his roles as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026. The company said it has begun ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
SS Innovations Reports Strong Q1 Growth and Expansion
Positive
May 13, 2026
On May 13, 2026, SS Innovations reported unaudited first-quarter 2026 results showing revenue more than doubled year over year to $11.1 million, driven by a sharp rise in SSi Mantra system sales, instrument and warranty revenue, and a 73.3% increa...
Business Operations and StrategyProduct-Related Announcements
SS Innovations Showcases Landmark Cross-Border Robotic Telesurgery
Positive
May 7, 2026
On May 2, 2026, SS Innovations completed a landmark long-distance cross-border telesurgery in which Dr. Mohit Bhandari performed a robotic gastrojejunostomy on a patient in Indore, India, while operating from the Royal Australian College of Surgeo...
Business Operations and StrategyProduct-Related Announcements
SS Innovations Marks Milestone in Robotic Surgery Adoption
Positive
May 5, 2026
On May 5, 2026, SS Innovations International reported that more than 10,500 cumulative surgeries had been successfully completed using its SSi Mantra surgical robotic system as of April 30, 2026, spanning over 170 procedure types and including mor...
Business Operations and StrategyProduct-Related Announcements
SS Innovations Showcases Next-Gen Robotic Surgery Platforms Globally
Positive
Apr 23, 2026
On April 23, 2026, SS Innovations International unveiled a slate of next-generation surgical robotic concepts at the Global Multi-Specialty Robotic Surgery Conference in New Delhi, India, which it hosted. The company showcased the under-developmen...
Business Operations and StrategyProduct-Related Announcements
SS Innovations Hosts Global Robotic and Telesurgery Conference
Positive
Apr 7, 2026
On April 7, 2026, SS Innovations International announced it would host the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India, from April 9–11, 2026, bringing together surgeons, innovators and healthcare leade...
Business Operations and StrategyProduct-Related Announcements
SS Innovations Gains New Global Approvals for SSi Mantra
Positive
Mar 30, 2026
On March 30, 2026, SS Innovations announced it had secured regulatory approvals for its SSi Mantra surgical robotic system for multiple indications in Colombia, Oman, Sri Lanka and Kenya, with approvals granted between November 2025 and January 20...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.